Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001654954-17-005040
Filing Date
2017-05-24
Accepted
2017-05-24 10:22:58
Documents
1
Period of Report
2017-06-29
Effectiveness Date
2017-05-24

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE 14A navb_def-14a.htm DEF 14A 1288775
  Complete submission text file 0001654954-17-005040.txt   1289935
Mailing Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017
Business Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35076 | Film No.: 17865695
SIC: 2835 In Vitro & In Vivo Diagnostic Substances